Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À¯¹æ¾Ï¿¡¼­ Topoisomerase¥±-¥á ¿Í c-erbB-2 ¹ßÇöÀÇ ÀÇÀÇ Expression of Topoisomerase¥±-¥á and c-erbB-2 in Breast Cancer

´ëÇÑ¿Ü°úÇÐȸÁö 2002³â 62±Ç 5È£ p.359 ~ 365
Á¤Å¼º, ±è¹ü±Ô, Â÷¼ºÀç, ¹Ú¼ºÀÏ, ÀÓÇö¹¬, ¹Ú¼ºÁØ, ÀÌÅÂÁø,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤Å¼º ( Chung Tae-Sung ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

±è¹ü±Ô ( Kim Beom-Gyu ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
Â÷¼ºÀç ( Cha Sung-Jae ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
¹Ú¼ºÀÏ ( Park Sung-Il ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÀÓÇö¹¬ ( Lim Hyun-Muk ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
¹Ú¼ºÁØ ( Park Sung-Jun ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç
ÀÌÅÂÁø ( Lee Tae-Jin ) 
Áß¾Ó´ëÇб³ ÀÇ°ú´ëÇÐ ¿Ü°úÇб³½Ç

Abstract


Purpose: Topoisomerase¥±-¥á is a key enzyme in DNA replication and a molecular target for many anti-cancer drugs. The C-erbB-2 oncogene (HER-2/neu) is the most frequently amplified oncogene in breast cancer. Because of the physical proximity of c-erbB-2 and topoisomerase¥±-¥á, co-amplification of the c-erbB-2 and topoisomerase¥±-¥á may occur. To investigate the clinical significance of the topoisomerase¥±-¥á and c-erbB-2, the correlation between topoisomerase¥±-¥á and c-erbB-2 was examined by immunohistochemical staining in 43 invasive ductal breast carcinomas and its relationship with other prognostic factors.


Methods: Topoisomerase¥±-¥á and c-erbB-2 expression was studied immunohistochemically using sections of formalin fixed, paraffin-embedded tumor specimens from 43 invasive ductal breast carcinomas. The correlation between topoisomerase¥±-¥á and c-erbB-2 expression, and its relationship with the clinicopathological factors such as the tumor size, lymph node metastasis, TNM stage, histological grade, nuclear grade, estrogen receptors and progesteron receptors was investigated.


Results: C-erbB-2 was expressed in 9 (20.9%) out of the 43 infiltrating ductal carcinoma cases. Among the prognostic factors, the tumor size, lymph node metastasis, tumor stage, nuclear grade, status of progesteron receptors and estrogen receptors did not significantly correlated with c-erbB-2 expression. The tumor size, lymph node metastasis, tumor stage, histological grade, and the absence of estrogen receptors displayed a significant relationship with the increase in the topoisomerase-¥á index. However, the topoisomerase¥±-¥á index did not correlate with the nuclear grade and the status of progesterone receptors. The topoisomerase¥±-¥á index was slightly higher in the c-erbB-2 positive expression cases compared to c-erbB-2 negative expression cases but this increase was not significant (P=0.503).


Conclusions: These results suggest that topoisomerase¥±-¥á may play some role as a prognostic factor, but further investigation is needed.

Å°¿öµå

Topoisomerase¥±-¥á; c-erbB-2; À¯¹æ¾Ï; Topoisomerase¥±-¥á; c-erbB-2; Breast cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS